StockData
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Surrozen, Inc./DE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.84+0.40 (+1.71%)

Close on Oct 19, 2026

Market cap
$551.80M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 6, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026After market close$5.00M$-0.41–
Q1 FY2026
Ended Mar 31, 2026
May 6, 2026After market close$5.00M$-11.65–
Q4 FY2025
Ended Dec 31, 2025
Mar 23, 2026After market close$500.00K$-20.13–
Q3 FY2025
Ended Sep 30, 2025
Nov 7, 2025After market close$983.00K$-8.36–
Q2 FY2025
Ended Jun 30, 2025
Aug 8, 2025After market close$1.00M$2.55–
Q1 FY2025
Ended Mar 31, 2025
May 9, 2025After market close$1.00M$-7.43–
Q4 FY2024
Ended Dec 31, 2024
Mar 31, 2025After market close–––
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024Before market open$10.00M$-0.44–
Q2 FY2024
Ended Jun 30, 2024
Aug 12, 2024After market close–$-7.99–
Q3 FY2023
Ended Sep 30, 2023
Nov 8, 2023After market close–$-0.34–
Q2 FY2023
Ended Jun 30, 2023
Aug 9, 2023After market close–$-0.31–

Press releases

Announcements Surrozen filed with the SEC